AD
The deal follows a state-led lawsuit and public outcry over the potential sale of sensitive genetic data of some 15 million customers.
The 23andMe headquarters in Sunnyvale, Calif., on Feb. 1, 2024. Justin Sullivan/Getty Images
|Updated:
23andMe co-founder and former CEO Anne Wojcicki has agreed to repurchase the bankrupt genetics firm for $305 million, after her nonprofit outbid pharmaceutical giant Regeneron in a court-supervised auction.
The deal, announced in a June 13 press release, was struck between 23andMe and TTAM Research Institute, a California-based medical research organization led by Wojcicki. It nullifies a previously announced $256 million acquisition agreement with Regeneron after the court reopened bidding in response to Wojcicki’s higher offer.
